ACP Letters of Support for the CREATES Act of 2017, H.R. 2212

Jonni M.

Prescription drug prices; generic drugs; biologics; biologicals; biosimilars; low-cost prescription drugs; brand-name prescription drugs; drug manufacturers; pharmaceutical companies; pharma; rising costs of prescription drugs; patient access to prescription drugs; Committee on the Judiciary; Sen. Chuck Grassley; Sen. Mike Lee; Sen. Patrick Leahy; Sen. Amy Klobuchar; Rep. Tom Marino; Rep. David Cicilline; Food and Drug Administration; FDA; CREATES Act of 2017; S. 974; H.R. 2212; Creating and Restoring Equal Access To Equivalent Samples Act of 2017; Risk Evaluation and Mitigation Strategies; REMS; Elements to Assure Safe Use; ETASU; prescription drug safety programs and protocols; medications

Thu, 05/11/2017 - 12:58 PM EDT

Thu, 05/11/2017 - 1:30 PM EDT

2

house_letter_in_support_of_creates_act_2017.pdf

{"Author":"Jonni M.","CreationDate":"2017-05-11T12:58:36-04:00","Creator":"Microsoft\u00ae Word 2010","Keywords":"Prescription drug prices; generic drugs; biologics; biologicals; biosimilars; low-cost prescription drugs; brand-name prescription drugs; drug manufacturers; pharmaceutical companies; pharma; rising costs of prescription drugs; patient access to prescription drugs; Committee on the Judiciary; Sen. Chuck Grassley; Sen. Mike Lee; Sen. Patrick Leahy; Sen. Amy Klobuchar; Rep. Tom Marino; Rep. David Cicilline; Food and Drug Administration; FDA; CREATES Act of 2017; S. 974; H.R. 2212; Creating and Restoring Equal Access To Equivalent Samples Act of 2017; Risk Evaluation and Mitigation Strategies; REMS; Elements to Assure Safe Use; ETASU; prescription drug safety programs and protocols; medications","ModDate":"2017-05-11T13:30:20-04:00","Producer":"Microsoft\u00ae Word 2010","Title":"ACP Letters of Support for the CREATES Act of 2017, H.R. 2212","Pages":2,"dc:format":"application\/pdf","dc:creator":"Jonni M.","dc:title":"ACP Letters of Support for the CREATES Act of 2017, H.R. 2212","dc:subject":["Prescription drug prices","generic drugs","biologics","biologicals","biosimilars","low-cost prescription drugs","brand-name prescription drugs","drug manufacturers","pharmaceutical companies","pharma","rising costs of prescription drugs","patient access to prescription drugs","Committee on the Judiciary","Sen. Chuck Grassley","Sen. Mike Lee","Sen. Patrick Leahy","Sen. Amy Klobuchar","Rep. Tom Marino","Rep. David Cicilline","Food and Drug Administration","FDA","CREATES Act of 2017","S. 974","H.R. 2212","Creating and Restoring Equal Access To Equivalent Samples Act of 2017","Risk Evaluation and Mitigation Strategies","REMS","Elements to Assure Safe Use","ETASU","prescription drug safety programs and protocols","medications"],"xmp:createdate":"2017-05-11T12:58:36-04:00","xmp:creatortool":"Microsoft\u00ae Word 2010","xmp:modifydate":"2017-05-11T13:30:20-04:00","xmp:metadatadate":"2017-05-11T13:30:20-04:00","pdf:producer":"Microsoft\u00ae Word 2010","pdf:keywords":"Prescription drug prices; generic drugs; biologics; biologicals; biosimilars; low-cost prescription drugs; brand-name prescription drugs; drug manufacturers; pharmaceutical companies; pharma; rising costs of prescription drugs; patient access to prescription drugs; Committee on the Judiciary; Sen. Chuck Grassley; Sen. Mike Lee; Sen. Patrick Leahy; Sen. Amy Klobuchar; Rep. Tom Marino; Rep. David Cicilline; Food and Drug Administration; FDA; CREATES Act of 2017; S. 974; H.R. 2212; Creating and Restoring Equal Access To Equivalent Samples Act of 2017; Risk Evaluation and Mitigation Strategies; REMS; Elements to Assure Safe Use; ETASU; prescription drug safety programs and protocols; medications","xmpmm:documentid":"uuid:426d65f0-3a40-41da-878d-05c2263d4f9b","xmpmm:instanceid":"uuid:722eaf87-72c7-4e76-be25-a545781e546e"}

2017